European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy

Thomas Powles; Michael Staehler; Börje Ljungberg; Karim Bensalah; Steven E Canfield; Saeed Dabestani; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Alessandro Volpe; Axel Bex

doi:10.1016/j.eururo.2016.06.009

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy

Thomas Powles
, Michael Staehler
, Börje Ljungberg
, Karim Bensalah
, Steven E Canfield
, Saeed Dabestani
, Rachel H Giles
, Fabian Hofmann
, Milan Hora
, Markus A Kuczyk
, Thomas Lam
, Lorenzo Marconi
, Axel S Merseburger
, Alessandro Volpe
, Axel Bex

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

Original language	English
Pages (from-to)	705–706
Journal	European Urology
Volume	70
Issue number	5
DOIs	https://doi.org/10.1016/j.eururo.2016.06.009
Publication status	Published - Nov 2016

Keywords

Nivolumab
Cabozantinib
Renal cancer
Guidelines
European Association of Urology

Access to Document

10.1016/j.eururo.2016.06.009

92-mainFinal published version, 354 KBLicence: Taverne

Cite this

Powles, T., Staehler, M., Ljungberg, B., Bensalah, K., Canfield, S. E., Dabestani, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., Volpe, A., & Bex, A. (2016). European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy. European Urology, 70(5), 705–706. https://doi.org/10.1016/j.eururo.2016.06.009

@article{85eb5a652ac54990aa81fc17d5754684,

title = "European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy",

abstract = "The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.",

keywords = "Nivolumab, Cabozantinib, Renal cancer, Guidelines, European Association of Urology",

author = "Thomas Powles and Michael Staehler and B{\"o}rje Ljungberg and Karim Bensalah and Canfield, \{Steven E\} and Saeed Dabestani and Giles, \{Rachel H\} and Fabian Hofmann and Milan Hora and Kuczyk, \{Markus A\} and Thomas Lam and Lorenzo Marconi and Merseburger, \{Axel S\} and Alessandro Volpe and Axel Bex",

year = "2016",

month = nov,

doi = "10.1016/j.eururo.2016.06.009",

language = "English",

volume = "70",

pages = "705–706",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "5",

}

Powles, T, Staehler, M, Ljungberg, B, Bensalah, K, Canfield, SE, Dabestani, S, Giles, RH, Hofmann, F, Hora, M, Kuczyk, MA, Lam, T, Marconi, L, Merseburger, AS, Volpe, A & Bex, A 2016, 'European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy', European Urology, vol. 70, no. 5, pp. 705–706. https://doi.org/10.1016/j.eururo.2016.06.009

TY - JOUR

T1 - European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy

AU - Powles, Thomas

AU - Staehler, Michael

AU - Ljungberg, Börje

AU - Bensalah, Karim

AU - Canfield, Steven E

AU - Dabestani, Saeed

AU - Giles, Rachel H

AU - Hofmann, Fabian

AU - Hora, Milan

AU - Kuczyk, Markus A

AU - Lam, Thomas

AU - Marconi, Lorenzo

AU - Merseburger, Axel S

AU - Volpe, Alessandro

AU - Bex, Axel

PY - 2016/11

Y1 - 2016/11

N2 - The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

AB - The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

KW - Nivolumab

KW - Cabozantinib

KW - Renal cancer

KW - Guidelines

KW - European Association of Urology

U2 - 10.1016/j.eururo.2016.06.009

DO - 10.1016/j.eururo.2016.06.009

M3 - Article

C2 - 27349614

SN - 0302-2838

VL - 70

SP - 705

EP - 706

JO - European Urology

JF - European Urology

IS - 5

ER -

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this